Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Max Born and Carl Bosch*
Cancer continues to be a global health challenge, necessitating the development of effective anticancer medications. Camptothecin and its derivative, topotecan, are prominent chemotherapeutic agents that have demonstrated promising efficacy against various types of cancers. This dissertation aims to comprehensively investigate the novel method of action employed by camptothecin and topotecan in combating cancer. By elucidating the molecular mechanisms and cellular targets involved, this study sheds light on the pharmacological principles underlying the therapeutic potential of these drugs. The findings from this research may contribute to the development of improved treatment strategies for cancer patients. Camptothecin and its derivative, topotecan, have emerged as promising chemotherapeutic agents with potent anticancer properties. This dissertation investigates the novel methods of action employed by camptothecin and topotecan, shedding light on their mechanisms at the molecular level. The study encompasses a comprehensive literature review, experimental data analysis, and an exploration of potential future directions for research and therapeutic applications.